Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Research & Development of $22.51 million for Q2 2026, unchanged from $22.51 million a year earlier and up 16.6% from the prior quarter.
Powered by 
Analysis
Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Metagenomi Therapeutics' Research & Development came in at $88.6 million, down 8.7% year-over-year; for FY2025, it came in at $94.43 million, down 13.5% from FY2024.
- By year, Research & Development came in at $109.18 million in FY2024 (+15.7%) and $94.4 million in FY2023.
- Five-year quarterly Research & Development spans a low of $19.3 million in Q1 2026 and a high of $31.44 million in Q1 2024.
- The high point for year-over-year Research & Development in five years was Q1 2024 (growth of 56.2%); the low point was Q1 2026 (a decline of 23.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $19.3 million (Q1 2026), $21.5 million (Q4 2025) and $25.28 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Metagenomi Therapeutics | 30.98 Mn | -574.76 Mn | - | 22.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.51 Mn |
| Mar 31, 2026 | 19.30 Mn |
| Dec 31, 2025 | 21.50 Mn |
| Sep 30, 2025 | 25.28 Mn |
| Jun 30, 2025 | 22.51 Mn |
| Mar 31, 2025 | 25.14 Mn |
| Dec 31, 2024 | 23.16 Mn |
| Sep 30, 2024 | 26.26 Mn |
| Jun 30, 2024 | 28.32 Mn |
| Mar 31, 2024 | 31.44 Mn |
| Dec 31, 2023 | 24.76 Mn |
| Sep 30, 2023 | 26.84 Mn |
| Jun 30, 2023 | 22.68 Mn |
| Mar 31, 2023 | 20.13 Mn |
API Access
Metagenomi Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();